AstraZeneca Announced Earlier It Entered Exclusive Global License Agreement With Dizal For Novel Oral EGFR Inhibitor Zegfrovy For Lung Cancer; AstraZeneca To Pay $600M Upfront, Up To $900M In Milestones, Plus Royalties